Pfizer fails in late-stage trial for sickle cell disease therapy

1 hour ago 1

Healthcare

Comments

Pfizer Makes $1.95 Billion Deal With U.S. For Future COVID-19 Vaccine

Pfizer (NYSE:PFE) announced Friday that a late-stage clinical trial for inclacumab, its experimental therapy for the blood disorder sickle cell disease, did not meet the main goal, marking the latest setback for its SCD portfolio.

Citing data from its Phase

Recommended For You

More Trending News

Read Entire Article

Pfizer fails in late-stage trial for sickle cell disease therapy

Recommended For You

More Trending News

Related

Texas AG launches probe into Xcel Energy, other utility comp...

You’re welcome, world: U.S. tariffs may cool inflation for t...

Wingstop's Smart Kitchen is a 'game changer' for the company...

Market Voices: Goolsbee on Fed rates, Buffet-UnitedHealth, C...

Par Technology rises after rating upgrade at BTIG

ICU Medical wins bullish view at Piper Sandler on upcoming p...

Warren Buffett’s $1.6 billion bet on UnitedHealth sends the ...

HHS reinstates childhood vaccines task force

Jollibee Foods Corporation Non-GAAP EPS of Php 2.78, revenue...

Trump’s 29-year-old crypto guru Bo Hines is juggling dozens ...

WI2WI reports Q2 results

Silver Scott Mines, Inc. reports Q2 results

Even the tooth fairy is cutting back. The average price per ...

Celcuity targets $5B addressable market as gedatolisib posts...

Capstone Holding Corp. GAAP EPS of -$0.13, revenue of $12.85...

Gang violence in Haiti is so bad the government is hiring 20...

Cycurion GAAP EPS of -$0.15, revenue of $3.89M

Galaxy Digital secures $1.4B financing to expand Helios AI d...

Short interest ticks up in S&P 500 Materials sector; Albemar...

SWK Holdings signals ongoing capital returns and streamlined...

Trending

Popular

عکس پربازدید از فرزند تازه متولد شده پیمان‌قاسم‌خانی

عکس | ماه کامل بر فراز حرم امام حسین (ع)